Why the study?
Does azilsartan medoxomil improve antihypertensive efficacy compared to other ARBs and ACE inhibitors in patients with arterial hypertension?
Does azilsartan medoxomil improve antihypertensive efficacy compared to other ARBs and ACE inhibitors in patients with arterial hypertension?
This review summarizes the pharmacological profile, antihypertensive efficacy, and pleiotropic effects of the angiotensin II receptor blocker azilsartan medoxomil.
Azilsartan medoxomil's profile merits targeted trials; leaves open routine preference over other ARBs pending prospective data.
This article deals withthe overview of the pharmacological characteristics of one class of antihypertensive drugs - angiotensin II receptor antagonists (ARA II) and new member of this class - azilsartan medoxomil (Edarbi®).We have analyzed the antihypertensive efficacy of different ARA, as well as azilsartan medoxomil efficacyin case of monotherapy and in comparison with other ARA and angiotensin-converting enzyme inhibitorsamong different groups of patients.The article describes the pleiotropic effects of azilsartan medoxomil, discovered nowadays.
No takes yet. Share an insight, caveat, or question.
М. Г. Бубнова (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: